Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species

被引:100
作者
Cat, Bahar
Stuhlmann, Dominik
Steinbrenner, Holger
Alili, Lirija
Holtkoetter, Olaf
Sies, Helmut
Brenneisen, Peter [1 ]
机构
[1] Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-40225 Dusseldorf, Germany
[2] Henkel KGAA, D-40191 Dusseldorf, Germany
关键词
myofibroblast; reactive oxygen species; transforming growth factor beta; tumor invasion; tumor-stroma interaction;
D O I
10.1242/jcs.03011
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Myofibroblasts, pivotal for tumor progression, populate the microecosystem of reactive stroma. Using an in vitro tumor-stroma model of skin carcinogenesis, we report here that tumor-cell-derived transforming growth factor beta 1 (TGF beta 1) initiates reactive oxygen species-dependent expression of alpha-smooth muscle actin, a biomarker for myofibroblastic cells belonging to a group of late-responsive genes. Moreover, protein kinase C (PKC) is involved in lipid hydroperoxide-triggered molecular events underlying transdifferentiation of fibroblasts to myofibroblasts (mesenchymal-mesenchymal transition, MMT). In contrast to fibroblasts, myofibroblasts secrete large amounts of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6), resulting in a significant increase in the invasive capacity of tumor cells. The thiol N-acetyl-L-cysteine, the micronutrient selenite as well as selenoprotein P and the lipid peroxidation inhibitors alpha-tocopherol and butylated hydroxytoluene significantly lower both the number of TGF beta 1-initiated myofibroblasts and the secretion of HGF, VEGF and IL-6, correlating with a diminished invasive capacity of tumor cells. This novel concept of stromal therapy, namely the protection of stromal cells against the dominating influence of tumor cells in tumor-stroma interaction by antioxidants and micronutrients, may form the basis for prevention of MMT in strategies for chemoprevention of tumor invasion.
引用
收藏
页码:2727 / 2738
页数:12
相关论文
共 71 条
  • [1] Cytokines facilitate chemotactic motility of breast carcinoma cells
    Arihiro K.
    Oda H.
    Kaneko M.
    Inai K.
    [J]. Breast Cancer, 2000, 7 (3) : 221 - 230
  • [2] DEPENDENCE OF COLLAGEN REMODELING ON ALPHA-SMOOTH MUSCLE ACTIN EXPRESSION BY FIBROBLASTS
    ARORA, PD
    MCCULLOCH, CAG
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1994, 159 (01) : 161 - 175
  • [3] TERMINAL DIFFERENTIATION, AGING, APOPTOSIS, AND SPONTANEOUS TRANSFORMATION IN FIBROBLAST STEM-CELL SYSTEMS INVIVO AND INVITRO
    BAYREUTHER, K
    FRANCZ, PI
    GOGOL, J
    KONTERMANN, K
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1992, 663 : 167 - 179
  • [4] Tumor-stroma interactions
    Bhowmick, NA
    Moses, HL
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) : 97 - 101
  • [5] Gefitinib therapy for non-small cell lung cancer
    Birnbaum A.
    Ready N.
    [J]. Current Treatment Options in Oncology, 2005, 6 (1) : 75 - 81
  • [6] BOUKAMP P, 1982, JNCI-J NATL CANCER I, V68, P415
  • [7] Central role of ferrous/ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts
    Brenneisen, P
    Wenk, J
    Klotz, LO
    Wlaschek, M
    Briviba, K
    Krieg, T
    Sies, H
    Scharffetter-Kochanek, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (09) : 5279 - 5287
  • [8] Down-modulation of nuclear localisation and pro-fibrogenic effect of 4-hydroxy-2,3-nonenal by thiol- and carbonyl-reagents
    Chiarpotto, E
    Allasia, C
    Biasi, F
    Leonarduzzi, G
    Ghezzo, F
    Berta, G
    Bellomo, G
    Waeg, G
    Poli, G
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2002, 1584 (01): : 1 - 8
  • [9] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867
  • [10] DAMOUR O, 1994, CLIN MATER, V15, P273, DOI 10.1016/0267-6605(94)90057-4